Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Will mesenchymal stem cells be future directions for treating radiation-induced skin injury?

Fang Z., Chen P., Tang S., Chen A., Zhang C., Peng G.

Clinical Trial on Chronic Inflammation, Immune Modulation, published in Stem Cell Res Ther (2021) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2021)
Reported sample size
—
Source database
Europe PMC
PMID
33712078
PMCID
PMC7952822
DOI
10.1186/s13287-021-02261-5
Citations
13

Abstract (original English)

Radiation-induced skin injury (RISI) is one of the common serious side effects of radiotherapy (RT) for patients with malignant tumors. Mesenchymal stem cells (MSCs) are applied to RISI repair in some clinical cases series except some traditional options. Though direct replacement of damaged cells may be achieved through differentiation capacity of MSCs, more recent data indicate that various cytokines and chemokines secreted by MSCs are involved in synergetic therapy of RISI by anti-inflammatory, immunomodulation, antioxidant, revascularization, and anti-apoptotic activity. In this paper, we not only discussed different sources of MSCs on the treatment of RISI both in preclinical studies and clinical trials, but also summarized the applications and mechanisms of MSCs in other related regenerative fields.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsHumansRadiation InjuriesMesenchymal Stem Cell TransplantationCell DifferentiationImmunomodulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research